What happened when CMTA-supported scientists at the University of Miami applied a piece of genetic tape to the gene mutation that causes CMT2E?
CMTA-STAR Alliance Partner Doses First CMT2S Patient
CMTA-STAR Alliance Partner Doses First CMT2S Patient
CMTA Awards $225,483 for Study on Using ASOs to Treat CMT2E
CMTA approved a $225,483 research award to Mario Saporta, MD, PhD, at the University of Miami to study the use of antisense oligonucleotides (ASOs) as a potential treatment approach for CMT2E.
